These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 34763158

  • 1. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
    Liang Q, Xu H, Liu Y, Zhang W, Sun C, Hu M, Zhu Y, Tan S, Xu X, Wang S, Liu L.
    Lung Cancer; 2021 Dec; 162():86-89. PubMed ID: 34763158
    [Abstract] [Full Text] [Related]

  • 2. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
    Guo W, Liang J, Zhang D, Huang X, Lv Y.
    Medicine (Baltimore); 2022 Oct 07; 101(40):e30913. PubMed ID: 36221356
    [Abstract] [Full Text] [Related]

  • 3. Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance.
    Liu D, Xu X, Wen J, Zhang C, Fan M.
    Lung Cancer; 2021 Oct 07; 160():32-35. PubMed ID: 34391065
    [Abstract] [Full Text] [Related]

  • 4. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
    Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT.
    J Thorac Oncol; 2019 Jul 07; 14(7):1233-1243. PubMed ID: 30902613
    [Abstract] [Full Text] [Related]

  • 5. A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
    Liu L, Hou F, Liu Y, Li W, Zhang H.
    J Natl Compr Canc Netw; 2021 Nov 11; 20(1):2-6. PubMed ID: 34763318
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.
    Yin Q, Guo T, Zhou Y, Sun L, Meng M, Ma L, Wang X.
    Thorac Cancer; 2022 Feb 11; 13(4):637-642. PubMed ID: 34964276
    [Abstract] [Full Text] [Related]

  • 7. Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
    Bokhari AA, Lai WY, Le AT, Gabre JL, Chuang TP, Fransson S, Bergman B, Djos A, Chen N, Martinsson T, Van den Eynden J, Doebele RC, Palmer RH, Hallberg B, Umapathy G.
    Lung Cancer; 2022 Sep 11; 171():103-114. PubMed ID: 35933914
    [Abstract] [Full Text] [Related]

  • 8. Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib.
    Chen Y, Zhang X, Jiang Q, Wang B, Wang Y, Junrong Y.
    Lung Cancer; 2020 Aug 11; 146():370-372. PubMed ID: 32527613
    [Abstract] [Full Text] [Related]

  • 9. Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.
    Song P, Zhang J, Shang C, Zhang L.
    Thorac Cancer; 2018 Oct 11; 9(10):1327-1332. PubMed ID: 30133144
    [Abstract] [Full Text] [Related]

  • 10. A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.
    Tian X, Liao Q, Yang Q, Chen L, Xiao M, Cheng Y.
    Invest New Drugs; 2022 Aug 11; 40(4):850-853. PubMed ID: 35441911
    [Abstract] [Full Text] [Related]

  • 11. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
    Li M, An Z, Tang Q, Ma Y, Yan J, Chen S, Wang Y.
    J Cell Mol Med; 2021 Oct 11; 25(19):9476-9481. PubMed ID: 34541785
    [Abstract] [Full Text] [Related]

  • 12. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.
    Woo CG, Seo S, Kim SW, Jang SJ, Park KS, Song JY, Lee B, Richards MW, Bayliss R, Lee DH, Choi J.
    Ann Oncol; 2017 Apr 01; 28(4):791-797. PubMed ID: 28039177
    [Abstract] [Full Text] [Related]

  • 13. Coexistence of a novel SETD2-ALK, EML4-ALK double-fusion in an advanced lung adenocarcinoma patient after alectinib resistant and response to immunotherapy combined with chemotherapy: a case report.
    Zhu L, Qin J.
    Discov Oncol; 2023 Apr 13; 14(1):44. PubMed ID: 37055606
    [Abstract] [Full Text] [Related]

  • 14. Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report.
    Xia H, Liang B, Liu G, Qi Y, Luo N, Li M.
    Medicine (Baltimore); 2022 Apr 08; 101(14):e29134. PubMed ID: 35446297
    [Abstract] [Full Text] [Related]

  • 15. Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion.
    Lin X, Yang X, Tan Y, Duan Q, He M.
    Invest New Drugs; 2022 Oct 08; 40(5):1160-1163. PubMed ID: 35608716
    [Abstract] [Full Text] [Related]

  • 16. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
    Isozaki H, Hotta K, Ichihara E, Takigawa N, Ohashi K, Kubo T, Ninomiya T, Ninomiya K, Oda N, Yoshioka H, Ichikawa H, Inoue M, Takata I, Shibayama T, Kuyama S, Sugimoto K, Harada D, Harita S, Sendo T, Tanimoto M, Kiura K.
    Clin Lung Cancer; 2016 Nov 08; 17(6):602-605. PubMed ID: 27405684
    [Abstract] [Full Text] [Related]

  • 17. Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
    Cai C, Tang Y, Li Y, Chen Y, Tian P, Wang Y, Gong Y, Peng F, Zhang Y, Yu M, Wang K, Zhu J, Lu Y, Huang M.
    Lung Cancer; 2021 Feb 08; 152():104-108. PubMed ID: 33444901
    [Abstract] [Full Text] [Related]

  • 18. Lung adenocarcinoma with an uncommon CCDC85A-ALK fusion responding to alectinib: A case report.
    Lin J, Wang W, Lin J, Chen R, Cao Y.
    J Cell Mol Med; 2022 Oct 08; 26(20):5326-5329. PubMed ID: 36102237
    [Abstract] [Full Text] [Related]

  • 19. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
    Li Z, Li P, Yan B, Gao Q, Jiang X, Zhan Z, Yan Q, Lizaso A, Huang C.
    Thorac Cancer; 2020 Jan 08; 11(1):176-180. PubMed ID: 31766077
    [Abstract] [Full Text] [Related]

  • 20. EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib.
    Matsuda H, Hara M, Iwakami SI, Takahashi K.
    BMJ Case Rep; 2021 Apr 27; 14(4):. PubMed ID: 33906872
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.